Saturday September 21, 2019 10:14
Food and Healthcare Press Releases
On Tuesday 17th, September 2019, Hotel Baraquda Pattaya - MGallery and Mercure Pattaya Hotel attended to Accor Pattaya Blood Donation #3/2019 at Veranda Resort Pattaya Na Jomtien - MGallery, MM Meeting Room. The event started at 10.00 a.m. to 02.00 p.m.
Upjohn Thailand announced its commitment and integrated strategy to improve patient health and relieve the burden of non-communicable diseases (NCDs) with trusted, quality medicines for every patient, everywhere. As Upjohn expands its capability in
According to new data from the CONCLUDE head-to-head trial, Tresiba(R) (insulin degludec) showed an overall lower risk of hypoglycaemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in
This year crosses 100 strategic partnerships in over 20 cities across Malaysia, Singapore, Indonesia, Thailand and Hong Kong. Since commenced operations in 2015, BookDoc has grown exponentially with four consecutive years of over 450% annual growth rate
FDI World Dental Federation (FDI) welcomes the long overdue commitment to strengthening oral health in the UN Political Declaration on Universal Health Coverage (UHC). The declaration will be officially adopted by world leaders at the UN High-Level
Novo Nordisk announced today the results from two Ozempic(R) (once-weekly semaglutide 1.0 mg) head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which showed: - Ozempic(R) was superior to treatment with the SGLT-2 inhibitor canagliflozin
Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in
New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (≥10 years of diagnosis) not optimally controlled on their current basal-bolus
"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global
Strekin AG (www.strekin.com), a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with
- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal
Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the
SpePharm AG, a subsidiary of Norgine B.V., announced that the United States District Court for the District of Delaware ruled on 4th September 2019 in favour of SpePharm in its proceeding against Eisai Inc., upholding SpePharm's licensed rights for
By Stephen Conchie, Senior Vice President and Managing Director, Herbalife Nutrition Asia Pacific At some point in your life, you may have dreamt to start your own business; interestingly, this aspiration is shared by the large majority in Thailand, nine
Occlutech AG announced today that its atrial flow regulator, the Occlutech AFR device, has obtained CE mark approval clearing it for sales on the European CE regulated market. Occlutech AFR is a next generation intra-atrial shunt device, intended to
- Cleft lip and palate (clefts) are the most common birth difference of the face and mouth. - Clefts happen when certain body parts and structures do not fuse together during fetal development and impact the development of the mouth, gums, and palate. -
Today during the ADA FDI World Dental Congress in San Francisco, USA, FDI World Dental Federation (FDI) released its latest resources on the treatment and care of patients with partial tooth loss. Rather than losing all their teeth as they age, more and
Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclude its ongoing
Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of
A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) agonist, may help to address the gap in managing the residual risk of heart attacks and strokes in high-risk patients, according to over 50
The world famous medical journal The Lancet has published the results of a two year health impact trial in Bangladesh. Less than 5% of studies submitted to this peer reviewed journal are published. In this trial, the impact of using "Aquatabs Flo" at
- Milestone contract signed between leading Chinese orthopaedic medtech supplier and Singapore based Asian subsidiary and hub of German world-market and technology leader in the area of bioabsorbable metallic implants for use in orthopaedic and trauma
Healthcare and Information Management Systems Society Asia Pacific (HIMSS APAC) เตรียมจัดงานประชุมและนิทรรศการ HIMSS AsiaPac19 Conference & Exhibition ระหว่างวันที่ 7-10 ตุลาคม 2562 ณ เซ็นทาราแกรนด์และบางกอกคอนเวนชันเซ็นเตอร์ กรุงเทพฯ